Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chewy Inc (CHWY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Chewy Inc vs Recursion Pharmaceuticals Inc — how do they compare? Chewy Inc trades at $22.38 (market cap $9.20B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Chewy Inc is far larger — about 5.1× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

CHWYRXRX
Market Cap
$9.20B$1.81B
Sector
Consumer CyclicalHealth
52-Week High
$42.33$6.79
52-Week Low
$17.51$2.84
Enterprise Value
$9.16B$1.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chewy Inc

CHWY trades at $22.38, down 0.93% on the day, with a bearish technical signal and neutral oscillators. Revenue grew to $11.86B in 2025, with net income surging to $392.74M, though margins remain thin. Recent news highlights insider selling and mixed institutional moves, while analyst consensus is strongly bullish with an $33.82 price target.

The stock offers growth potential from recurring revenue and market expansion but faces risks from competition and volatile earnings. With high valuation multiples and bearish technicals, near-term pressure may persist, but long-term prospects hinge on sustained profitability and execution against rivals like Amazon.

Recursion Pharmaceuticals Inc

RXRX trades at $3.29, showing no change in the last session. The stock exhibits a bullish technical signal with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a Q2 2026 loss of $0.25 per share, missing estimates, with revenues declining year-over-year. Recent news highlights ongoing investor conferences and partnership advancements, such as Genentech optioning a neuroscience target, but profitability remains a challenge with a net income margin of -961.97% for 2026.

The outlook for RXRX is mixed, with analyst consensus leaning hold (60%) due to high cash burn and unproven commercial scalability. Investment opportunity lies in its AI-driven drug discovery platform and partnerships, but risks include sustained losses, competitive pressures, and reliance on milestone payments. The stock's trajectory hinges on pipeline success and cost management improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Chewy Inc

Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.

Read more on CHWY

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX